References
- Miller R., Mitchell J., Lyon M., Moore D. Riluzole for amyotrophic laterals sclerosis (ALS)/motor neuron disease (MND). Cochrane database syst rev 2007; 1: CD001447
- Gordon P. H., Doorish C., Montes J., Mosley R. L., Diamond B., Macarthur R. B., et al. Randomized controlled phase II trial of glatiramer acetate in ALS. Neurology 2006; 66: 1117–9
- Cheung Y. K., Gordon P. H., Levin B. Selecting promising ALS therapies in clinical trials. Neurology 2006; 67: 1748–51
- Great Lakes ALS Study Group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. Neurology 2003; 61: 1503–7
- Schmidt E. P., Drachman D. B., Wiener C. M., Clawson L., Kimball R., Lechtzin N. Pulmonary predictors of survival in amyotrophic lateral sclerosis: use in clinical trial design. Muscle & Nerve 2006; 33: 127–32
- Miller R. G., Rosenberg J. A., Gelinas D. F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence‐based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311–1323
- Levy G., Kaufmann P., Buchsbaum R., Montes J., Barsdorf A., Arbing R., et al. A two‐stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology 2006; 66: 660–3
- Scelsa S. N., MacGowan D. J., Mitsumoto H., Imperato T., LeValley A. J., Liu M. H., et al. A pilot, double‐blind, placebo‐controlled trial of indinavir in patients with ALS. Neurology 2005; 64: 1298–1300
- Miller R. G., Bradley W., Cudkowicz M., Meininger V., Mitsumoto H., Sauer D., et al. Phase II/III controlled trial of TCH 346 in patients with amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis. 2005 (Suppl 1); 6: 13
- A Multi‐Center, Phase III, Randomized, Double Blind, Placebo‐controlled, Clinical Trial of Minocycline in ALS. http://clinicaltrials.gov/ct/show/NCT00047723;jsessionid = CC70D058431C30F123A07EF3E9A7CB4A?order = 3
- Florence J. M., Moore D. H., Mendoza M., Mass J., Renna R., Malinowski L., et al. Validation of telephonic administration of the ALSFRS‐R. Neurology 2004; 62 (Suppl 5): A134
- Kasarskis E. J., Dempsye‐Hall L., Luu L. C., Mendiondo M., Kryscio R. Rating the severity of ALS by caregivers over the phone using the ALSFRS‐R. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 50–4
- Kaufmann P., Levy G., Montes J., Buchsbaum R., Barsdorf A. I., Battista V., et al. Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2006, (in press)
- Montes J., Levy G., Albert S., Kaufmann P., Buchsbaum R., Gordon P. H., et al. Development and evaluation of a self‐administered version of the ALSFRS‐R. Neurology 2006; 67: 1294–6